BRUSSELS, June 7 (Reuters) - Thrombogenics NV:
* Presented data show Microplasmin cures approximately 50% of patients with
macular hole
* Macular hole results are further data from already reported phase III trial
((Brussels newsroom; +32 2 287 6810))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Presented data show Microplasmin cures approximately 50% of patients with
macular hole
* Macular hole results are further data from already reported phase III trial
((Brussels newsroom; +32 2 287 6810))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
© 2010 AFX News
